The deal between the two biopharmaceutical giants will boost the purchaser’s cancer drug portfolio.

The massive sum will buy out Kite Pharma, whose cancer therapy is expected to be among the first of its type approved by the FDA.

The scientific supply giant seeks to expand into biopharma development and manufacturing.  

On Tuesday, shareholders at the agribusiness giant approved the $66 billion deal with the European pharmaceutical firm.

The Swiss pharma giant is acquiring Oklahoma-based Selexys Pharmaceuticals, a maker of drugs for inflammatory and thrombotic diseases.

The Ireland-based pharma company makes a $1.7 billion offer to acquire Tobira Therapeutics, a US firm developing liver disease drugs.

The Irish drugmaker has made a $639 million dollar offer to buy the US-based biopharma.

The US agribusiness behemoth agreed to a $57 billion buyout offer from the European pharmaceutical giant.

The pharma giant is purchasing the San Francisco–based cancer drugmaker to boost its oncology portfolio.